血管内皮细胞生长因子(VEGF)及其受体在肿瘤血管新生中起重要作用，阻断VEGF的生成已成为抗肿瘤治疗的新靶点。
Vascular endothelial growth factor (VEGF) and its receptor play a critical role in tumor-associated angiogenesis and have become the new targets of anti-tumor therapy.
目前，已有两种具有广谱抗肿瘤活性且无明显副作用的血管生成抑制剂面世。
Two angiogenesis inhibitors have been developed that have a broad spectrum of anticancer activity, yet virtually no side effects.
抑制肿瘤血管生成和抑制肿瘤细胞的侵袭和黏附、运动能力等可能是该方抗肿瘤转移的重要机制之一。
Inhibited tumor Angiogenesis and Inhibited tumor cell's invasion, adhesion, motor abilities could be important mechanisms of QRXJR in anti-metastasis.
血管生成与肿瘤的生长、侵袭和转移密切相关，目前，以抑制血管生成为靶点治疗肿瘤有望成为抗肿瘤新疗法之一。
Angiogenesis is required for invasive tumor growth and metastasis. Inhibition of angiogenesis is considered to be a promising approach of antitumor therapy.
本文就肿瘤血管生成、VEGF家族的特性、VEGF在抗肿瘤药物开发中的应用做一综述。
This thesis gives a review on tumor angiogenesis, the features of VEGF family, the application of VEGF on anti - tumor drugs.
治疗方面，内用药物主要有抗肿瘤药物、环孢素A、维甲酸、抗菌药、生物制品、血管生成拮抗剂等。
On treatment, the oral medication mainly include anti-tumor drug, CyA, VA, anti-bacterium drug, biological products and blood vessel formation antigeon and so on.
治疗方面，内用药物主要有抗肿瘤药物、环孢素A、维甲酸、抗菌药、生物制品、血管生成拮抗剂等。
On treatment, the oral medication mainly include anti-tumor drug, CyA, VA, anti-bacterium drug, biological products and blood vessel formation antigeon and so on.
应用推荐